Fatigue; Myalgias; Acute generalized exanthematous pustulosis; This literature-non-study case was reported in a literature article and describes the occurrence of ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS (Acute generalized exanthematous pustulosis) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.   LITERATURE REFERENCE: Agaronov A, Makdesi C, Hall CS. Acute generalized exanthematous pustulosis induced by Moderna COVID-19 messenger RNA vaccine. JAAD Case Rep. 2021     Concurrent medical conditions included Anaphylactic reaction (Patient had a past medical history of anaphylactic reaction to tetracyclines).    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS (Acute generalized exanthematous pustulosis) (seriousness criterion medically significant), FATIGUE (Fatigue) and MYALGIA (Myalgias). The patient was treated with DIPHENHYDRAMINE for Adverse event, at an unspecified dose and frequency and HYDROCORTISONE for Adverse event, at an unspecified dose and frequency. At the time of the report, ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS (Acute generalized exanthematous pustulosis) had resolved and FATIGUE (Fatigue) and MYALGIA (Myalgias) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Physical examination: abnormal (abnormal) showed variously sized erythematous and edematous papules and plaques on the abdomen, neck, and chest. Within the inframammary folds were numerous nonefollicular-based pinpoint pustules.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS (Acute generalized exanthematous pustulosis), FATIGUE (Fatigue) and MYALGIA (Myalgias) to be possibly related.    Concomitant medications were not provided. Patient had subjective fever, fatigue, myalgias, and a mildly pruritic eruption under the breasts within a few hours of vaccination.  Over the course of 3 days, the eruption spread to her abdomen, neck, and chest. The patient tried diphenhydramine and over-the-counter hydrocortisone 1% cream without relief. One week after the onset of the eruption, desquamation began in the inframammary region. The eruption completely resolved after 12 days. The patient was in normal health with no recent symptoms and had no history of drug consumption in the 72 hours prior to vaccination.  Company Comment: Very limited information regarding the events onset and vaccination dates has been provided at this time and insufficient to assess the temporal association. A causal relationship cannot be excluded. Additional information has been requested.; Sender's Comments: Very limited information regarding the events onset and vaccination dates has been provided at this time and insufficient to assess the temporal association. A causal relationship cannot be excluded. Additional information has been requested.